Cancer Genetics and Epigenetics 2019, Vol.7, No.1, 1-10
3
Table 1 Characteristics of included studies
Reference
Country
NPC
Diagnostic
Source of
Control
Genotype
HWE
Total
Propro
Argpro
ArgArg
method
control
Total
Propro
Argpro
ArgArg
method
Yung 1997 China (Hong Kong) 20
3
11
6
Histological
HB
31
8
13
10
PCR-RFLP
0.380
Golovleva 1997 China
64
23
26
15
Histological
HB
99
23
46
30
PCR-RFLP
0.511
Tsai 2002
China (Taiwan)
50
16
14
20
Histological
HB
59
8
26
25
PCR-RFLP
0.765
Tiwawech 2003
Thailand
102
26
52
24
Histological
HB
148
28
70
50
PCR-RFLP
0.691
Sousa 2006
Portugal
107
13
32
62
Histological
PB
285
14
93
178
AS-RFLP
0.682
Hadhri-Guiga 2007 Tunisia
115
23
48
44
NA
HB
83
6
45
32
PCR-RFLP
0.065
Xiao 2010
China
522
135
270
117
Histological
HB
712
120
366
226
PCR-RFLP
0.170
Xie 2013
China
42
6
16
20
Histological
HB
31
6
13
12
PCR-RFLP
0.474
Zhang 2014
China
566
141
292
133
Histological
HB
477
118
229
130
PCR-RFLP
0.392
Note: NPC, nasopharyngeal carcinoma; HPV, human papillomavirus; NA, not available; HB, hospital-based; PB, population-based; HWE, Hardy Weinberg Equilibrium
